A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 10,900 shares of VIRX stock, worth $2,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,900
Previous 5,900 84.75%
Holding current value
$2,398
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.5 - $1.17 $22,481 - $52,605
-44,962 Reduced 2.87%
1,520,240 $820,000
Q1 2024

May 15, 2024

BUY
$0.48 - $1.13 $17,342 - $40,826
36,130 Added 2.36%
1,565,202 $1.6 Million
Q4 2023

Feb 14, 2024

BUY
$0.44 - $1.04 $3,813 - $9,014
8,668 Added 0.57%
1,529,072 $871,000
Q3 2023

Nov 14, 2023

BUY
$1.03 - $1.58 $62 - $96
61 Added 0.0%
1,520,404 $1.58 Million
Q2 2023

Aug 14, 2023

SELL
$0.89 - $2.13 $32,912 - $78,767
-36,980 Reduced 2.37%
1,520,343 $2.14 Million
Q1 2023

May 15, 2023

BUY
$1.38 - $2.29 $5,028 - $8,344
3,644 Added 0.23%
1,557,323 $2.48 Million
Q4 2022

Feb 14, 2023

SELL
$1.26 - $4.38 $10,503 - $36,511
-8,336 Reduced 0.53%
1,553,679 $2.27 Million
Q3 2022

Nov 14, 2022

BUY
$3.32 - $5.69 $19,232 - $32,962
5,793 Added 0.37%
1,562,015 $6.67 Million

Others Institutions Holding VIRX

About Viracta Therapeutics, Inc.


  • Ticker VIRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,558,200
  • Market Cap $8.26M
  • Description
  • Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...
More about VIRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.